Dr Stanton says she and her team are delighted that their six-year project to make a handheld point-of-care diagnostic device a reality has come to fruition.
"We are immensely proud that we have created this brilliant device; there is currently no other system in the world that compares in terms of the analytical power we have achieved at this level of mobility and ease of use."
Dr Stanton's team includes a physicist, computer programmer, a chemist and biologists. Their project was funded through a New Economy Research Fund (NERF) grant, from what is now New Zealand's Ministry of Business, Innovation and Employment. NERF objectives include supporting investigator-initiated basic research that has the potential to create the advanced technological platforms that will underpin new and emerging industries.
The University's commercialization arm, Otago Innovation, is now working to spin out the technology in partnership with a New Zealand company named Ubiquitome.
Otago Innovation's Senior Commercialization Manager David Christensen says that Freedom4's development exemplifies university research being successfully translated into real-world technology with enormous potential health, economic and environmental benefits.
"Dr Stanton and her colleagues have used their combined multidisciplinary expertise to overcome a number of daunting technical challenges to create a molecular diagnostic device that is truly world-leading," Mr Christensen says.
It is another great example of technology transfer from the University of Otago, he says.
"We are delighted to be a part of Ubiquitome as it works to realize its dream of connecting the world to meaningful genomic information through handheld, cloud-connected genetic analysis devices."
|Contact: Dr. Jo-Ann Stanton|
University of Otago